THE LYMPHOMA STUDY ASSOCIATION

Their core work

LYSA is a French cooperative clinical research group focused exclusively on lymphoma and related hematological cancers, operating a network of clinical trial sites across France and beyond. Their core activity is designing and running clinical trials, collecting real-world patient outcomes data, and feeding curated, disease-specific datasets into large-scale research platforms. In both their H2020 projects — HARMONY and HARMONY PLUS — they contributed lymphoma clinical data and disease expertise to a pan-European big data initiative for hematological malignancies, helping translate raw patient data into actionable insights for drug developers and clinicians. They sit at the intersection of clinical oncology practice and data-driven research infrastructure.

What they specialise in

How they've shifted over time

In their first H2020 engagement (HARMONY, from 2017), LYSA's contribution centered on disease-specific patient data: lymphoma, leukemia, myelodysplastic syndromes, multiple myeloma, and childhood cancers — classic clinical cooperative group territory. By the time HARMONY PLUS launched in 2020, the focus had broadened into molecular genetics, translational medicine, digital health outcomes, and even business model design for sustaining the data platform beyond project funding. This shift reflects a maturation from pure clinical data provider toward a partner that understands how patient data creates durable research and commercial value — a meaningful evolution for any consortium builder considering them.

LYSA is moving from disease-specific data contributor toward a partner with capacity for molecular-level translational research and data platform sustainability — making them increasingly relevant for precision oncology and health data commercialization projects.

How they like to work

LYSA participates exclusively as a consortium partner — they have never led an H2020 project — which fits the profile of a specialist clinical network that brings curated patient data and disease expertise rather than project management infrastructure. Both their projects are within the same HARMONY ecosystem, suggesting they operate through sustained, deep partnerships rather than broad opportunistic participation. With 57 unique partners across 13 countries accumulated through just two projects, they work inside very large, diverse consortia where their role is clearly defined and high-value rather than generalist.

LYSA has reached 57 unique consortium partners across 13 countries through participation in just two large-scale projects, indicating their network is dense and well-connected rather than broad and shallow. Their geographic reach is distinctly European, anchored in major hematology research nations.

What sets them apart

LYSA is one of France's leading lymphoma cooperative groups, with decades of clinical trial infrastructure and access to curated patient cohorts that most research institutions cannot replicate. What sets them apart is the combination of disease specificity — few organizations know lymphoproliferative disorders at this depth — with an established network of clinical sites that can contribute real-world, trial-grade patient data to large platforms. For any consortium targeting hematological malignancy data, especially for IMI-style public-private partnerships, LYSA is among a very small number of European cooperative groups that can deliver this combination credibly.

Highlights from their portfolio

• HARMONY
  The largest hematological malignancy big data initiative in H2020, with LYSA serving as a key clinical data contributor for lymphoma, spanning a 6-year run (2017-2023) and receiving the larger share of LYSA's total EU funding.
• HARMONY PLUS
  The direct evolution of HARMONY, expanding into molecular genetics and digital health outcomes, signaling LYSA's deepening role in precision oncology data infrastructure beyond simple clinical data supply.